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Abstract. Lipids such as ceramides (Cer) and phosphatidylcholines (PC) have been found altered in the plasma of Alzheimer’s
disease (AD) patients in a number of discovery studies. For this reason, the levels of 6 ceramides and 3 PCs, with different fatty
acid length and saturation levels, were measured in the plasma from 412 participants (AD n = 205, Control n = 207) using mass
spectrometry coupled with ultra-performance liquid chromatography. After this, associations with AD status, brain atrophy,
and age-related effects were studied. In the plasma of AD participants, cross-sectional analysis revealed elevated levels of
three ceramides (Cer16:0 p < 0.01, Cer18:0 p < 0.01, Cer24:1 p < 0.05). In addition, two PCs in AD plasma (PC36:5 p < 0.05,
PC38:6 p < 0.05) were found to be depleted compared to the control group, with PC36:5 also associating with hippocampal
atrophy (p < 0.01). Age-specific analysis further revealed that levels of Cer16:0, Cer18:0, and Cer20:0 were associated with
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hippocampal atrophy only in younger participants (age < 75, p < 0.05), while all 3 PCs did so in the older participants (age > 75,
p < 0.05). PC36:5 was associated with AD status in the younger group (p < 0.01), while PC38:6 and 40:6 did so in the older
group (p < 0.05). In this study, elevated ceramides and depleted PCs were found in the plasma from 205 AD volunteers.
Our findings also suggest that dysregulation in PC and ceramide metabolism could be occurring in different stages of AD
progression.
Keywords: Alzheimer’s disease, brain atrophy, ceramide, phosphatidylcholine
INTRODUCTION
Alzheimer’s disease (AD) is the most common
form of dementia accounting for 60–80% of all cases,
representing 44 million cases globally with the num-
ber of diagnoses expected to triple by 2050 [1, 2].
The neurological disorder results from the cell loss
triggered by a not well-understood metabolic cascade
that involves numerous extrinsic and intrinsic path-
ways. Among these, lipid signaling pathways have
attracted attention as an important and possibly crit-
ical factor in neurodegeneration [3–6].
Ceramides (Cer) have been linked to neurode-
generative disease by a growing body of evidence.
Altered ceramide levels have been reported in AD
cerebrospinal fluid (CSF) [7] and in AD brain [8].
More recently, Mielke et al. [9] found higher serum
Cer16:0 and Cer24:0 levels to be linked with an
increased risk of developing AD. In addition to
ceramides, phosphatidylcholines (PCs) have been
shown to be associated with AD. We previously iden-
tified a panel of three PCs, PC (16:0, 20:5), PC (16:0,
22:6), and PC (18:0, 22:6), that were decreased in
the plasma of AD patients in comparison to cogni-
tively normal controls and mild cognitive impairment
patients [10]. This relatively underpowered study
(n = 35–40) showed that a predictive performance
of APOE of 67% was increased to 83% by includ-
ing APOE and PCs as markers [10]. A study by
Mapstone et al. in plasma also reported a panel of
ten lipids, which included seven PCs, to be predic-
tive of AD phenoconversion [3], although this result
was not replicated in serum in a recent follow-up
study [11].
Together these findings suggest that lipids play a
crucial role in AD pathology and may represent a
valuable clinical tool for diagnosis and prevention.
The untargeted approach is ideal in discovering new
lipids associated with AD, as it scans for thousands of
lipid molecules in each sample. More targeted analy-
ses achieve better quality data for fewer lipid entities,
usually up to 200 lipids. It is also essential to repli-
cate results in larger cohorts when possible [12, 13]
and analyze how these effects depend on the other
major factors of AD—namely APOE status and age.
Here we measured levels of 9 abundant plasma lipids
previously linked to AD [8–10], in plasma from AD
and elderly control volunteers, and studied whether
any trends in the amounts of these lipids were asso-
ciated to AD, brain atrophy, APOE status and age of
participants.
MATERIALS AND METHODS
Patient details and blood collection
This study utilized 412 plasma samples (205 AD
and 207 controls) from the Dementia Case Register
(DCR) at King’s College London and the EU funded
AddNeuroMed study [10, 14]. Of these 412 partic-
ipants 122 also had structural magnetic resonance
imaging (sMRI) data. Normal elderly control subjects
were recruited from non-related family members of
AD patients, care-givers’ relatives, social centers for
the elderly, or GP surgeries, and had no evidence
of cognitive impairment. AD individuals were pri-
marily recruited from local memory clinics. Relevant
ethics boards approved the studies and informed con-
sent was obtained for all subjects. Each patient was
required to fast for two hours prior to sample col-
lection and 10 ml of blood was then collected in
tubes coated with sodium ethylenediaminetetraacetic
acid (EDTA) to prevent clotting. Whole blood was
centrifuged to form a plasma supernatant, which in
turn was removed and placed at –80◦C until further
use. The sample demographics showing health and
clinical characteristics of participants, by diagnostic
group, are shown in Table 1.
Measurements of lipid levels
Samples from the two clinical cohorts were pre-
pared and analyzed separately. The first cohort (DCR,
n = 98) was analyzed in 2012 where depletion of
the three PCs was first reported [10]. Meanwhile
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Table 1
Demographic characteristics of participants in study samples from DCR and AddNeuroMed. p-values are obtained from the comparison
between AD and control groups
AD Control p-value
(n = 205) (n = 207)
Average age (s.d)1 77.35 (6.88) 74.88 (6.60) 2.26 × 10−4A
Gender (Male/Female)1 81/123 77/130 0.60 B
APOE 4, no. (%)1 124 (61.03) 60 (29.13) 5.85 × 10−11B
Average white matter (s.d)2 0.6561 (0.0733) 0.6985 (0.0408) 9.30 × 10−5A
Average Hippocampus Volume (s.d)2 0.003678 (0.000757) 0.004969 (0.000628) 4.84 × 10−18A
Average Entorhinal Volume (s.d)2 0.001870 (0.000556) 0.002516 (0.000437) 7.43 × 10−11A
Average Entorhinal Thickness (s.d)2 5.4709 (0.9866) 6.8090 (0.7207) 1.62 × 10−14A
Average HDL-c (s.d)3/mmolL−1 1.58 (0.37) 1.55 (0.38) 0.068C
Average LDL-c (s.d)3/mmolL−1 3.42 (1.01) 3.07 (0.82) 0.529C
Average TC (s.d)3/mmolL−1 5.69 (1.17) 5.29 (1.01) 0.229C
Average TG (s.d) 3/mmolL−1 1.64 (1.04) 1.52 (0.67) 0.885C
Statins (Yes/No)4 38/97 34/108 0.509B
HDL-c, high density lipoprotein-cholesterol; LDL-c, low density lipoprotein-cholesterol; TC, total cholesterol; TG, triglycerides. 1AD
n = 202, CTL n = 206. 2AD n = 52, CTL n = 70. 3AD n = 102, CTL n = 106. 4AD n = 135, CTL n = 142. AStudent t-test. BChi-square test.
CLinear regression after adjusting for age, gender, the APOE 4 allele and the center of origin of each sample.
sample analysis from the second cohort (AddNeu-
roMed, n = 314) was carried out in 2014 using the
identical methodology. Lipid extraction and analysis
methods have been described elsewhere [12, 15] and
can also be found in the Supplementary Material S1.
The single molecule integrated peak areas under
the exact mass chromatographs of the nine lipids
and the internal standard (Tripentadecanoin) were
obtained by using QuanLynx (MassLynx 4.1, Waters)
by setting up an integration parameter file using the
average mass charge ration (m/z) and retention time
of the 9 lipids and internal standard. The integration
parameters used in lipid measurement can be found in
the Supplementary Material S2. Tolerances for mass
and retention time of 0.1 Da and 5 min, respectively,
were typically applied. Lipids with the levels below
the limit of quantification were not used for statistical
analyses. Lipids PC (16:0, 20:5), PC (16:0, 22:6), and
PC (18:0, 22:6) were referred as (PC36:5, PC38:6,
PC40:6) and ceramides were referred as (Cer16:0,
Cer18:0, Cer20:0, Cer22:0, Cer24:0, and Cer24:1)
throughout the manuscript.
sMRI data acquisition and analysis
Volumes of hippocampi, white matter, entorhi-
nal cortices, and entorhinal cortex thickness (ER
thickness), normalized by intracranial volume, were
obtained from 122 subjects (52 AD patients and 70
Controls) who had undergone sMRI. The volumetric
data were not used to aid in the clinical diagnosis of
AD. Detailed information regarding data acquisition,
pre-processing, and quality control assessment have
been described for this cohort elsewhere [16, 17].
Statistical analysis
We applied generalized linear models (GLM) to
compare lipid levels in the AD group relative to
the Control group, and to study their relationship
with brain atrophy. The GLM included covariates
to control for center of origin of each sample, gen-
der, age, APOE status, batch effect, and internal
standard. When the analysis was segregated accord-
ing to age, the GLMs were separately applied to
two non-intersecting age bins, corresponding to per-
centiles 0–50th and 50–100th. Each one of these bins
therefore contained the same number of samples (ca.
n = 170 for status, n = 60 for sMRI). More detailed
methodology on the statistical analysis carried out in
the Results section can be found in the Supplementary
Material S3. Figure 1 shows a schematic workflow of
the data used in this study.
RESULTS
Participant characteristics
The demographic characteristics (age, gender,
APOE, cholesterol levels, triglyceride levels, and vol-
ume in four different brain regions) of participants
by diagnostic group, are shown in Table 1. AD par-
ticipants were slightly older than controls; this is
usual in AD studies with a relatively larger sample
size [18, 19]. The AD group had a higher percent-
age of APOE carriers and presence of brain atrophy
(p-values <0.001). There were no significant differ-
ences between the groups on high density lipoprotein,
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Fig. 1. Workflow of this study sMRI, structural magnetic resonance imaging.
low density lipoprotein, total cholesterol levels, and
total triglyceride levels.
Ceramides
Elevated ceramide levels in AD plasma
Six ceramide levels from 202 plasma samples from
the AD group and 207 plasma samples from the cog-
nitively healthy group were compared using GLM.
Figure 2 shows the distribution of all ceramides,
suggesting that some of them are elevated in the
AD group (in red). Table 2 confirms that sin-
gle molecule plasma levels of Cer16:0 (p < 0.01),
Cer18:0 (p < 0.01), and Cer24:1(p < 0.05) in partic-
ular were elevated, while no significant differences
were observed for Cer20:0, Cer22:0, and Cer24:0. T-
values were derived from GLM (Table 2) and showed
that the magnitude of the effect was the largest
for Cer18:0 (–2.99), followed by Cer16:0 (–2.94)
and Cer24:1 (–2.49). T-values for the non-significant
ceramides were, following the same order, Cer24:0
(–1.89), Cer20:0 (–1.75), and Cer22:0 (–1.42).
Using the same GLM approach, we then tested if
single ceramide levels would associate with atrophy
in white matter, hippocampus, entorhinal, and ER
thickness as measured in 122 participants. The statis-
tical results tabulated in Table 3 show that there was
no association between the ceramides and atrophy
Fig. 2. Data distributions. The figure shows the box plots corre-
sponding to each phosphatidylcholine (PC), each ceramide, and
each brain volume. All variables have been z-scored to ease visual
comparison. The sizes of the boxes represent the 25th and 75th
percentiles, while the central horizontal line dividing both boxes
represents the median, and the mean is represented as a rhomboid.
The length of each whisker extends to 1.5 times the length of the
box of its corresponding side. Samples beyond the length of the
whiskers are represented as induvial black dots.
in these four brain regions. Figure 3 summarizes
these associations, including ceramides and PCs in
the same figure for comparison.
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Fig. 3. Effects found with generalized linear models (GLM). Sta-
tistical results of the GLM on the combined AD cohorts. Columns
represent AD demographics variables while rows represent the
lipids levels. Different shades of red indicate different standard
significance thresholds.
Table 2
Group differences in lipid levels between AD and control group.
The table shows the mean and standard deviation for each one of
the lipids measured in this study. Second column and third column
show mean and standard deviation (SD) values for the control
and AD population respectively. The last two columns show the
t-values and p-values derived from GLM for pairwise comparison
between the groups
Variables Control AD GLM
(Mean ± SD) (Mean ± SD) t-value p-value
PC36:51 0.03 ± 0.07 –0.30 ± 0.06 2.35 0.019
PC38:61 0.01 ± 0.06 –0.28 ± 0.06 2.13 0.034
PC40:61 0.01 ± 0.06 –0.27 ± 0.06 1.83 0.068
Cer16:02 –0.13 ± 0.07 0.10 ± 0.06 –2.94 0.004
Cer18:02 –0.09 ± 0.06 0.22 ± 0.07 –2.99 0.003
Cer20:02 –0.10 ± 0.06 0.01 ± 0.08 –1.75 0.081
Cer22:01 –0.06 ± 0.05 0.00 ± 0.06 –1.42 0.156
Cer24:01 –0.05 ± 0.05 0.03 ± 0.06 –1.89 0.060
Cer24:11 –0.06 ± 0.05 0.09 ± 0.06 –2.49 0.013
1n = 412; 2n = 314.
Table 3
p-values derived from GLM when testing for associations between
lipid levels and atrophies of 4 brain regions and APOE status
Variables APOE White Hippocampus Entorhinal ER
Matter Thickness
PC36:51 0.469 0.588 0.009 0.761 0.640
PC38:61 0.164 0.599 0.398 0.794 0.561
PC40:61 0.100 0.951 0.348 0.481 0.488
Cer16:02 0.833 0.592 0.172 0.557 0.307
Cer18:02 0.530 0.470 0.064 0.527 0.230
Cer20:02 0.961 0.208 0.165 0.909 0.981
Cer22:01 0.639 0.179 0.457 0.876 0.692
Cer24:01 0.347 0.344 0.694 0.972 0.891
Cer24:11 0.549 0.669 0.420 0.413 0.740
1n = 412; 2n = 314.
Table 4
Statistical power associated with each analysis. In this study, differ-
ent numbers of samples were available depending on the variables
that were compared (metabolites and demographics). The temporal
analysis of Fig. 5 further reduced the number of samples by a factor
of 2 for each age bin. The table indicates what is the minimum effect
size (in numbers of standard deviations) that could be detected with
a t-test for the available number of samples corresponding to each
comparison
Metabolites Demographics Age bins N Effect size∗
PC36:5 AD status None 412 0.14
PC38:6 APOE 2 206 0.20
PC40:6 White Matter None 122 0.26
Cer22:0 Hippocampus
Cer24:0 Entorhinal 2 61 0.36
Cer24:1 ER Thickness
Cer22:0 AD status None 314 0.16
APOE 2 157 0.22
Cer24:0 White Matter None 122 0.26
Cer24:1 Hippocampus
Entorhinal
ER Thickness 2 61 0.36
∗Effect size corresponding to power 80%.
Ceramides in age-bins
Previous GLM analyses (Fig. 3, Table 2) showed
Cer16:0, Cer18:0, and Cer24:1 associating with AD
status but not with brain atrophy. However, this
type of analysis (i.e., pooling all subjects together
independently of age) may mask some age-specific
associations (age trends of metabolite groups and
brain volumes shown in Fig. 4). To investigate for
this possibility, we further applied GLM on AD sta-
tus, brain volume measurements, and APOE status
in two non-intersecting age-bins. The results of these
analyses are summarized as line plots (Fig. 5 and
Supplementary Material S4). The analyses showed
no individual ceramides associating with AD clas-
sification and APOE status in any age-bins. When
we tested the ceramide levels on brain atrophy in
these same age-bins, ceramide levels were associated
with greater hippocampal volume loss in relatively
younger participants (Cer16:0, Cer18:0, and Cer20:0;
p-value <0.05 for age <75; see Fig. 5). In this age
bin, associations were also found with entorhinal
volume (Cer16:0, Cer18:0, Cer20:0, Cer22:0, and
Cer24:0), ER thickness (Cer16:0 and Ceer20:0), and
white matter (Cer20:0; see Supplementary Mate-
rial S4). In other participants (age >75), only white
matter atrophy was significantly associated with
Cer18:0, Cer20:0, and Cer22:0. There were no asso-
ciations between ceramides and entorhinal volume,
ER thickness, or hippocampal volume for older
participants.
Co
rre
cte
d P
roo
f
6 M. Kim et al. / Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume
Fig. 4. Comparisons on how variable groups (lipids and brain vol-
ume measurements) change with age in AD and control groups.
The y-axis represents the averages of three groups of variables,
namely: the six ceramides; the three phosphatidylcholines (PCs);
and the four brain volumes (from left panel to right panel). The
x-axis represents age. Each point presents a subject, while color
represents the diagnosis of each patient. Solid line represents
simple linear regression for each group, while the shaded area
represents the 0.95 confidence interval.
Phosphatidylcholines
Diminished phosphatidylcholine levels in AD
plasma
Three PC levels from 202 plasma samples from
the AD group and 207 plasma samples from the cog-
nitively healthy group were compared using GLM.
Figure 2 shows the distribution of all 3 PCs for ADs
and controls. Table 2 confirms that single molecule
measurements plasma levels of PC36:5 and PC38:6
were significantly reduced in abundance in the AD
group compared to healthy control group (p < 0.05 for
both PCs), while PC40:6 did not show a significant
change between the groups.
In Fig. 3, brain volume measurements in 122
participants showed PC36:5 positively associated
with hippocampal volume (p < 0.01). All other PC
associations failed to show significance (hippocam-
pus, entorhinal cortex thickness, and white matter
atrophy).
PCs in age-bins
We applied the same analysis in non-intersecting
age-bins, where PC36:5 revealed a strong associa-
tion with AD status in younger participants (age <75),
while PC38:6 and PC40:6 did so in the older age bin
(age >75, all p < 0.05). Associations of all PCs with
hippocampal volume, and of PC36:5 with entorhinal
volume, were found only in the older age bin. No
other associations were found with PCs when segre-
gating into older and younger participants (Fig. 5 and
Supplementary Material S4).
DISCUSSION
A number of reports have implicated lipid dys-
regulation in AD pathology [8–10]; to explore these
findings further, six ceramide and three phosphatidyl-
choline species were measured and compared
between AD and a cognitively healthy volunteers. We
tested whether lipid levels were associated with AD
diagnosis and brain atrophy, and after this, we divided
the samples into two non-intersecting age-bins, each
bin represented by the same number of participants,
and tested whether the associations between lipid
levels and AD would be significant in any of these
age-bins.
Fig. 5. Time or age-bin analyses. GLM were applied in two age bins to statistical significance of effects between lipids and three target
variables (APOE status, hippocampal volume, and AD diagnosis) based on GLM models. p-values are shown in log scale, with dotted lines
representing the p = 0.05 threshold.
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This study found that from the six abundant
ceramides measured in plasma and previously shown
to be implicated in AD, three ceramides, Cer16:0,
Cer18:0, and Cer24:1, were elevated in the plasma of
AD patients compared to cognitively healthy group.
As mentioned previously, there are several studies
that have reported ceramide elevation in AD brain [5,
8, 20] and others, which report increased expression
of sphingomyelinase, the enzyme that synthesizes
ceramides [21, 22]. Ceramide involvement in neu-
ronal death is likely to be related to its capability
to activate caspase 3 [23, 24]. Another possible fac-
tor is that in neurons, oxidative stress induced by
amyloid- accumulation can cause overexpression
of sphingomyelinase, this in turn causing elevated
ceramides. Interestingly, ceramides have also been
found to stimulate amyloid- production, which
again would result in an increased rate of neuronal
death [25].
With aging representing the greatest risk factor
for late-onset AD [26], we explored how associa-
tions between ceramides and AD classification varied
with age. In doing this, we found no associations
between ceramides and AD status in any of the two
age-bins. This result contrasted with the GLM models
when calculated with all the participants in the study
(Table 2 and Fig. 3) that showed three ceramides asso-
ciating with AD status. However this difference can
be attributed to the smaller sample size used in the
age-bins. As a reference, the minimum effect size
detectable (at 80% power) by a paired t-test when
using the full sample would vary between 0.14 and
0.26 standard deviations (depending on the number
of patients where lipids and imaging were measured),
with age-bin segregation increasing this minimum by
ca. 50% (see Table 4).
Despite the power limitations of segregating into
two bins, upon testing how relationships between
ceramide levels and hippocampal volume loss varied
with age, we observed levels of Cer16:0, Cer18:0,
and Cer20:0 elevated in the plasma of younger
participants (in ages below 75). Ceramides were
also frequently associated with entorhinal volume
and thickness in these younger participants (see
Fig. 4 and Supplementary Material S4). Hippocam-
pal and entorhinal atrophy is known to occur before
symptoms of cognitive decline during AD devel-
opment [27] and accumulation of ceramides have
been linked with a higher risk of developing AD
[9, 28]. Our data suggests that higher levels are
also detected in younger individuals with hippocam-
pal atrophy, potentially adding evidence to a role
in phenoconversion. This is very interesting since it
could mean that ceramides have an important role in
early diagnosis or as proposed by Mielke et al. [28],
in phenoconversion.
In addition to ceramides, we also measured
PC36:5, PC38:6, and PC40:6. These molecules were
linked to AD when they were found associated
with decline in AD cognitive function [10] and
memory loss in healthy aging [29]. After com-
paring the PC levels in 412 plasma samples, we
observed diminished PC36:5 and PC38:6 levels in
AD plasma, partially replicating our previous find-
ings. The lower PC levels reported here could be
as a result of upregulation of PC hydrolysis induced
by increased phospholipase A2 (PLA2) activity and
amyloid accumulation [30]. These PCs also contain
omega-3 poly-unsaturated fatty acids (ω-3 PUFA).
PC36:5 contains an eicosapentaenoic acid (EPA) as
part of its molecular structure, while PC38:6 con-
tains a docosahexaenoic acid (DHA) [10]. These
fatty acids are thought to be absorbed into the brain
when contained in molecules of another lipid family,
lysophosphatidylcholines, which are direct metabolic
products of PCs [31]. -3 PUFAs are well known for
their neuroprotective properties in brain with higher
omega-3 content being associated with lower inci-
dence of dementia [32, 33]. Higher PCs in plasma
(i.e., assuming higher -3 PUFA in plasma) could
have neuroprotective properties by increasing -3
PUFA present in the brain. This hypothesis could
be supported by a report which demonstrated that a
-3 PUFA containing PC diet resulted in increased
anti-inflammatory activity in the brain [34] and a
recent study examining 2,000 healthy patients that
found that during healthy-aging plasma shows an
increasing trend for PC levels [35]. We also observed
lower level of EPA containing PC36:5 associat-
ing with hippocampal atrophy, these initial finding
may be explained by EPA acting as an competitive
inhibitor of arachiodonic acid (AA) thus resulting
in down-regulation of pro-inflammatory AA-derived
metabolites such as eicosanoids [36, 37].
When we assessed how associations between PCs
and AD varied in different age-bins, we found that
PCs showed no associations with APOE, white mat-
ter, or entorhinal cortex thickness atrophy in the
two age-bins. However, all three PCs were associ-
ated with hippocampal volume in older participants,
while PC36:5 was also marginally associated with
entorhinal volume in this same age group. PC36:5
was strongly associated with AD in younger partic-
ipants, while PC38:6 and 40:6 were so in the older
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age bin, suggesting changes in peripheral PC levels
may be also age-related or related to the AD severity
stage.
In conclusion, we found the levels of two PCs and
three ceramides altered in AD plasma when com-
pared to cognitively healthy plasma. Ceramides were
found to be increased in AD and associated with
hippocampal and entorhinal atrophy in younger par-
ticipants (age <75). PCs were found decreased and
associated with status, especially in older participants
for PC38:6 and 40:6 (age >75), but in younger par-
ticipants for PC36:5. These results contribute to the
growing body of evidence that peripheral lipids are
implicated in AD pathology. More work is needed to
understand the relationships between plasma lipids
and AD progression, and importantly, to decipher if
they should be considered as biomarkers for diagnosis
or targets for AD therapies.
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